Triciribine, an AKT inhibitor, has been studied in phase I/II clinical trials and has shown effectiveness in reducing the risk of elevated Akt levels in patients with advanced hematological malignancies (AML, CCML, ALL, CLL) while inducing cell death through the modulation of Akt and its substrate BAD under well-tolerated conditions [106]. This evidence concerns the gene BAD and acute lymphoblastic leukemia.